How did lomustine become standard of care in recurrent glioblastoma?

Title
How did lomustine become standard of care in recurrent glioblastoma?
Authors
Keywords
Alkylation, CCNU, DNA, MGMT, Repair
Journal
CANCER TREATMENT REVIEWS
Volume 87, Issue -, Pages 102029
Publisher
Elsevier BV
Online
2020-05-05
DOI
10.1016/j.ctrv.2020.102029

Ask authors/readers for more resources

Reprint

Contact the author

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started